Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Rating of “Moderate Buy” from Brokerages

Keros Therapeutics, Inc. (NASDAQ:KROS) has earned an average recommendation of “Moderate Buy” from the fourteen analysts that are covering the stock, MarketBeat reports. Six investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $42.33.

A number of research analysts have recently commented on the stock. Oppenheimer reduced their price target on shares of Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating for the company in a research report on Thursday, January 16th. HC Wainwright reduced their target price on Keros Therapeutics from $47.00 to $40.00 and set a “buy” rating for the company in a research report on Thursday, February 27th. TD Cowen cut Keros Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. BTIG Research lowered Keros Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, December 12th. Finally, Wedbush downgraded shares of Keros Therapeutics from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $47.00 to $15.00 in a research note on Friday, January 17th.

Hedge Funds Weigh In On Keros Therapeutics

Large investors have recently added to or reduced their stakes in the business. Victory Capital Management Inc. purchased a new position in shares of Keros Therapeutics in the third quarter worth about $216,000. Intech Investment Management LLC bought a new position in Keros Therapeutics during the 3rd quarter worth approximately $603,000. Charles Schwab Investment Management Inc. increased its stake in Keros Therapeutics by 14.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 260,120 shares of the company’s stock worth $15,105,000 after purchasing an additional 32,492 shares during the period. FMR LLC lifted its position in Keros Therapeutics by 3.8% in the third quarter. FMR LLC now owns 4,899,134 shares of the company’s stock valued at $284,493,000 after purchasing an additional 179,374 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Keros Therapeutics by 59.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,371 shares of the company’s stock valued at $312,000 after purchasing an additional 1,994 shares during the period. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Stock Performance

Shares of KROS opened at $10.99 on Friday. Keros Therapeutics has a 52-week low of $9.78 and a 52-week high of $72.37. The stock’s 50-day simple moving average is $11.15 and its 200 day simple moving average is $34.88. The stock has a market capitalization of $445.78 million, a price-to-earnings ratio of -2.11 and a beta of 1.39.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.36) by $0.22. The firm had revenue of $3.04 million for the quarter, compared to the consensus estimate of $37.32 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. On average, research analysts forecast that Keros Therapeutics will post -4.74 earnings per share for the current fiscal year.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.